Half-year report · HY
2158.TEDINET S100X4KF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥6m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥290m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥23m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥544m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥296m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥20m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥296m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥73m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥555m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥206m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥73m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥206m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥102m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥753m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥369m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥254m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥123m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥689m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥913m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥564m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.86 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.25 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥5.24 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 39.1% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| DXreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| DXreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| DXreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥61m |
| Life Science AIreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥274m |
| Life Science AIreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥274m |
| Life Science AIreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥216m |
| Risk Managementreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Risk Managementreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Risk Managementreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥150m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | −¥6m |
| DXreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥154m |
| DXreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥154m |
| DXreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥34m |
| Life Science AIreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥140m |
| Life Science AIreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥140m |
| Life Science AIreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥122m |
| Risk Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Risk Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Risk Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥290m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 564
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 3637420 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.0926 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 2750000 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0700 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 2660300 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0677 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 391600 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0099 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 351700 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0089 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 260136 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0066 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 185500 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0047 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 178900 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0045 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 148424 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0037 | |
| Number of shares held | InterimInstant | 14599880 | |
| Shareholding ratio | InterimInstant | 0.3720 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 123400 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 391974 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 39197400 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 44062 | |
| Number of shares issued shares voting rights | InterimInstant | 39364862 | |
| Number of voting rights issued shares voting rights | InterimInstant | 391974 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 123400 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 123400 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0031 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 123400 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 123400 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0031 | |
| Number of male directors and other officers | FilingDateInstant | 8 | |
| Number of female directors and other officers | FilingDateInstant | 1 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.111 | |
| Cash and deposits | Prior1YearInstant | 2598740000 | JPY |
| Cash and deposits | InterimInstant | 1847603000 | JPY |
| Accounts receivable trade and contract assets ca | Prior1YearInstant | 1025684000 | JPY |
| Accounts receivable trade and contract assets ca | InterimInstant | 1185525000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 1863000 | JPY |
| Raw materials and supplies | InterimInstant | 23824000 | JPY |
| Work in process | Prior1YearInstant | 1900000 | JPY |
| Work in process | InterimInstant | 80231000 | JPY |
| Accounts receivable other | Prior1YearInstant | 45777000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |